Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Klaus Tamminen"'
Autor:
Tero Ylisaukko-oja, Minna Puttonen, Jari Jokelainen, Mirkka Koivusalo, Klaus Tamminen, Saku Torvinen, Markku Voutilainen
Publikováno v:
Scandinavian journal of gastroenterology. 57(4)
Dose-escalation is a common practice to optimize treatment with subcutaneously administered biologicals in Crohn's disease (CD) and ulcerative colitis (UC). However, limited data is available on the extent of dose-escalation in real-life. Here, we an
Autor:
Ilkka Vihriälä, Jari Punkkinen, Tero Ylisaukko-oja, Taina Sipponen, Eija Hirsi, Christian Nielsen, Jyrki Tillonen, Markku Pajala, Jouni Silvennoinen, Ville Liukkonen, Mikko Kellokumpu, Jari Jokelainen, Henna Rautiainen, Veikko Moilanen, Hans Henricson, Hannu Sulonen, Mirva Esterinen, Timo Blomster, Kari Toljamo, Klaus Tamminen, Pauliina Molander, Airi Jussila, Jaakko Aaltonen, Juha Kuisma, Petri Mäkelä, Kalle Hakala, Margus Lääne, Kimmo Salminen, Sauli Herrala, Ulla-Maija Suhonen, Mika Puhto, Markku Peräaho, Heikki Nuutinen
Publikováno v:
Scandinavian Journal of Gastroenterology. 53:158-167
Objectives: The efficacy and tolerability of vedolizumab in the treatment of inflammatory bowel diseases (IBD) has been demonstrated in an extensive GEMINI clinical trial programme. Clinical trials represent highly selected patient populations and, t
Autor:
Saku Torvinen, Jonna Salonen, Anu Marttila, Tatu Miettinen, Klaus Tamminen, Melissa Bauer, Jari Jokelainen, V. Vihervaara
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e224-e225
Autor:
Klaus Tamminen, Mikko Kellokumpu, Tero Ylisaukko-oja, Sauli Herrala, Markku Peräaho, Taina Sipponen, Henna Rautiainen, Petri Mäkelä, Jari Jokelainen, Ulla-Maija Suhonen, Heikki Nuutinen, Markku Pajala, Mirva Esterinen, Margus Lääne, Mika Puhto, Christian Nielsen, Jyrki Tillonen, Veikko Moilanen, Juha Kuisma, Ville Liukkonen, Kalle Hakala, Pauliina Molander, Hannu Sulonen, Saku Torvinen, Jaakko Aaltonen, Jouni Silvennoinen, Hans Henricson, Ilkka Vihriälä, Eija Hirsi, Kari Toljamo, Airi Jussila, Jari Punkkinen, Timo Blomster, Kimmo Salminen
Publikováno v:
Biologicals : journal of the International Association of Biological Standardization. 58
Limited data is available on vedolizumab combination therapies in real-world clinical practice. Here, we evaluated the concomitant corticosteroid, immunosuppressive, and 5-aminosalicylic acid utilization of inflammatory bowel disease (IBD) patients t
Autor:
Saku Torvinen, Anu Marttila, Melissa Bauer, Jonna Salonen, Tatu Miettinen, Klaus Tamminen, V. Vihervaara, Jari Jokelainen
Publikováno v:
International Journal of Clinical and Experimental Medical Sciences. 7:21
Multiple myeloma (MM) is one of the most prevalent hematologic cancers. Treatments of MM have been improved by availability of novel therapies but require regular hospital visits and intense patient follow-up. In this real-world study, patient charac
Publikováno v:
Current Medical Research and Opinion. 24:3453-3461
Budesonide/formoterol maintenance and reliever therapy has shown its effectiveness as a treatment for moderate-to-severe asthma.To explore the cost-effectiveness of budesonide/formoterol maintenance and reliever therapy as compared to fixed combinati
Autor:
Jaakko Aaltonen, Jari Jokelainen, Airi Jussila, Heikki Nuutinen, Timo Blomster, Anja Eberl, Tero Ylisaukko-oja, Klaus Tamminen, Taina Sipponen, Sauli Herrala, Markku Pajala
Publikováno v:
Gastroenterology. 152:S398
Publikováno v:
Blood. 128:5645-5645
Introduction: Identification of patients with high-risk (HR) multiple myeloma (MM) is important to optimise their treatment. In 2015, revised International Staging System (R-ISS) guidelines were published (Palumbo, 2015) where HR cytogenetics (CG) an
Autor:
Heikki Joensuu, M. Mäntylä, Klaus Tamminen, Paula Maasilta, Janusz Szopinski, Seppo Sarna, Tarja Ruotsalainen, Antti Jekunen, Maija Halme, Mikael Kajanti, Kari Cantell, Seppo Pyrhönen, Karin Mattson, A. Niiranen, Henrik Riska
Publikováno v:
University of Helsinki
Patients with any stage of small cell lung cancer were given low-dose interferon-alpha (IFN-alpha) from the first day of treatment as long as possible irrespective of changes in treatment dictated by disease progression. All patients received 6 cycle
Thirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma
Autor:
Olof Selroos, Tari Haahtela, Klaus Tamminen, Tore Persson, Paula Rytilä, Tuomo Kava, Kurt Nikander, L. Pekka Malmberg
Publikováno v:
The Journal of allergy and clinical immunology. 124(6)
Background In a 3-year study, adult patients who recently developed asthma (symptoms for less than 1 year) were treated for 2 years with the inhaled corticosteroid (ICS) budesonide (early therapy) or terbutaline. During the third year of the study, t